Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference
An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in the US – is also safe and generates a strong antibody response in
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
